Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754372 | 0.87 | MAPK1 (0.43) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6706821 | 0.87 | MMP13 (0.51) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6747097 | 0.86 | ALDH1A1 (0.43) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6706802 | 0.77 | NPC1 (0.51) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6705942 | 0.76 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2MMP13SLC22A8 | |
| SCHEMBL6742558 | 0.75 | MAPK1 (0.44) | MAPK1MMP13 | |
| SCHEMBL6753604 | 0.73 | POLB (0.43) | POLBNPC1RAB9ASMN1; SMN2PLA2G4B | |
| SCHEMBL6750636 | 0.68 | PTGER4 (0.38) | MAPK1 | |
| SCHEMBL10636593 | 0.67 | NPC1 (0.71) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL10530987 | 0.67 | POLB (0.55) | POLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | NAHRA JOE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014869-A2 | 5,6-FUSED 3,4-DIHYDROPYRIMIDINE-2-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043986-A1 | 5,6-Fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | POLB 1091/4885NPC1 2473/4885RAB9A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.